The recent COVID-19 pandemic has revealed the need to develop tests that are accurate,rapid, and inexpensive for the diagnosis of infectious diseases. This problem is relevantnot only for viruses, but also for bacteria and parasites: the identification ofpathogens at low concentrations by simple and accurate methods is still largelyunsatisfied because these microorganisms are structurally complex and are incorporated incomposite and diverse biological samples, which can create relevant interferences inpathogens' detection. Direct diagnostic approaches, such as microscopic examination,culture and molecular testing are carried out in equipped laboratories and require longwaiting times to obtain the results. Recently developed point-of-care (POC) tests are agroup of technologies that miniaturize tests into portable devices such that they can beperformed both in well-equipped laboratories and outside the conventional laboratorysetting. The present study aims to explore the feasibility and adaptability of newlydeveloped platforms to detect: 1. a virus (SARS-CoV2), 2. a bacterium (Pseudomonasaeruginosa) and 3. a protozoan parasite (Leishmania infantum) in clinical specimens, suchas blood and respiratory samples. These newly developed platforms are expected toovercome the current limitations of molecular testing (high cost, time required and needfor well-equipped laboratories) and rapid testing (high number of false-negativeresults). In addition, the newly developed platforms may have important clinicalapplication in low-income countries, which will benefit from a simple and inexpensiveapproach to detect the many infectious diseases that affect millions of people each year.